Stifel Reiterates Buy Rating on CTI BioPharma (CTIC) with $6.20 Price Target
Tweet Send to a Friend
Stifel analyst Benjamin Burnett reiterated a Buy rating and $6.20 price target on CTI BioPharma (NASDAQ: CTIC), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
